RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
Now, this is cool... https://t.co/lrzVWau36N
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @nacho_pelaez: Esto se parece cada día más a la mama https://t.co/zOuIEsSwwr
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
Esto se parece cada día más a la mama https://t.co/zOuIEsSwwr
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
RT @NatRevClinOncol: In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: ht…
In prostate cancer, luminal A/B & basal molecular subtypes predict prognosis & maybe response to postoperative ADT: https://t.co/UOptd73j1d
@JAMAOnc article from @DrSpratticus @felixfengmd et al on prognostic value of molecular subtyping in prostate cancer https://t.co/7p7Zui9k91 https://t.co/CcoDwu01jW
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
RT @NimaSharifiMD: Great study @felixfengmd @UCSFCancer! Question - what drives luminal A vs B biology? Subtyping of #ProstateCancer https…
RT @CleClinicUro: Associations of Luminal & Basal Subtyping of #ProstateCancer w/Prognosis and Response to ADT https://t.co/J2uSMb3AU0 via…
RT @CleClinicUro: Associations of Luminal & Basal Subtyping of #ProstateCancer w/Prognosis and Response to ADT https://t.co/J2uSMb3AU0 via…
Associations of Luminal & Basal Subtyping of #ProstateCancer w/Prognosis and Response to ADT https://t.co/J2uSMb3AU0 via @JAMA_current https://t.co/WiJzbPJYfl
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
RT @DrSpratticus: Luminal and Basal Subtyping of Prostate Cancer https://t.co/rjTkzVk0Hs. @felixfengmd @DrSpratticus @PCF_Science. Univ of…
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co…
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
RT @DrSpratticus: Luminal and Basal Subtyping of Prostate Cancer https://t.co/rjTkzVk0Hs. @felixfengmd @DrSpratticus @PCF_Science. Univ of…
Subtyping prostate cancer predictive response androgen deprivation https://t.co/eWTL3ni7UE
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
RT @JAMAOnc: #ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ck…
#ProstateCancer molec subtyping into luminal/basal prognostic for clin outcomes, predictive of benefit w ADT https://t.co/b3ckZRrxGY #PCSM
RT @DrSpratticus: Luminal and Basal Subtyping of Prostate Cancer https://t.co/rjTkzVk0Hs. @felixfengmd @DrSpratticus @PCF_Science. Univ of…
PAM50 Test for Luminal and Basal Subtyping of Prostate #Cancer https://t.co/ykk9pyz3n0 #research @nanostringtech https://t.co/1dmhsACd3N
RT @DrSpratticus: Luminal and Basal Subtyping of Prostate Cancer https://t.co/rjTkzVk0Hs. @felixfengmd @DrSpratticus @PCF_Science. Univ of…
RT @DrSpratticus: Luminal and Basal Subtyping of Prostate Cancer https://t.co/rjTkzVk0Hs. @felixfengmd @DrSpratticus @PCF_Science. Univ of…
Luminal and Basal Subtyping of Prostate Cancer https://t.co/rjTkzVk0Hs. @felixfengmd @DrSpratticus @PCF_Science. Univ of Michigan and UCSF
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation https://t.co/hV3IJoVKEP
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
RT @CedarsUroOncol: Great work from@felixfengmd - #PAM50 #luminal/#basal genotypes in #ProstateCancer https://t.co/11mP86maFz
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co…
RT @m0370: 乳癌に用いる多遺伝子発現アッセイPAM50で前立腺癌をluminal A,B,basalに分類(前立腺癌にHER2型は無い)。lum Bは予後不良だが内分泌療法に反応し、lum Aには内分泌療法は奏効しない。 /JAMA oncol https://t.c…
RT @NimaSharifiMD: Great study @felixfengmd @UCSFCancer! Question - what drives luminal A vs B biology? Subtyping of #ProstateCancer https…
RT @JAMAOnc: Luminal and Basal Subtyping of Prostate Cancer https://t.co/wQ6i969DpA
RT @charlesryanmd: Great Paper @felixfengmd Big change in how we subtype the disease: Luminal and Basal Subtyping of #ProstateCancer https…
RT @NimaSharifiMD: Great study @felixfengmd @UCSFCancer! Question - what drives luminal A vs B biology? Subtyping of #ProstateCancer https…
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
@felixfengmd @pcvblack Strong work by Dr. Felix and colleagues on clinical relevance of molecular subtypes in PC https://t.co/himr8MriEX
RT @CedarsUroOncol: Great work from@felixfengmd - #PAM50 #luminal/#basal genotypes in #ProstateCancer https://t.co/11mP86maFz
RT @NimaSharifiMD: Great study @felixfengmd @UCSFCancer! Question - what drives luminal A vs B biology? Subtyping of #ProstateCancer https…
RT @NimaSharifiMD: Great study @felixfengmd @UCSFCancer! Question - what drives luminal A vs B biology? Subtyping of #ProstateCancer https…
RT @NimaSharifiMD: Great study @felixfengmd @UCSFCancer! Question - what drives luminal A vs B biology? Subtyping of #ProstateCancer https…
RT @NimaSharifiMD: Great study @felixfengmd @UCSFCancer! Question - what drives luminal A vs B biology? Subtyping of #ProstateCancer https…
Great study @felixfengmd @UCSFCancer! Question - what drives luminal A vs B biology? Subtyping of #ProstateCancer https://t.co/auR8u8njmE
RT @CedarsUroOncol: Great work from@felixfengmd - #PAM50 #luminal/#basal genotypes in #ProstateCancer https://t.co/11mP86maFz
RT @JAMAOnc: Luminal and Basal Subtyping of Prostate Cancer https://t.co/wQ6i969DpA
Great work from@felixfengmd - #PAM50 #luminal/#basal genotypes in #ProstateCancer https://t.co/11mP86maFz
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co…
RT @JAMAOnc: Luminal and Basal Subtyping of Prostate Cancer https://t.co/wQ6i969DpA
Luminal and Basal Subtyping of Prostate Cancer https://t.co/wQ6i969DpA
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
RT @m0370: 乳癌に用いる多遺伝子発現アッセイPAM50で前立腺癌をluminal A,B,basalに分類(前立腺癌にHER2型は無い)。lum Bは予後不良だが内分泌療法に反応し、lum Aには内分泌療法は奏効しない。 /JAMA oncol https://t.c…
Faaascinating! https://t.co/95lVmqAhus
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
Luminal and Basal Subtyping of Prostate Cancer https://t.co/yOcbF0yZ4m https://t.co/3hSil4oI36
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co…
RT @m0370: 乳癌に用いる多遺伝子発現アッセイPAM50で前立腺癌をluminal A,B,basalに分類(前立腺癌にHER2型は無い)。lum Bは予後不良だが内分泌療法に反応し、lum Aには内分泌療法は奏効しない。 /JAMA oncol https://t.c…
乳癌に用いる多遺伝子発現アッセイPAM50で前立腺癌をluminal A,B,basalに分類(前立腺癌にHER2型は無い)。lum Bは予後不良だが内分泌療法に反応し、lum Aには内分泌療法は奏効しない。 /JAMA oncol https://t.co/w8SMAbA3Nr
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co…
@ProstateCancerC @PCFnews @ProstateUK Can this do for #prostatecancer what #oncotype did for #breastcancer ? https://t.co/f0zbPor57G
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
RT @dr_coops: PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.…
PAM50 luminal/basal breast ca signature also classifies prostate ca @felixfengmd @UCSFUrology @UCSFCancer @JAMAOnc https://t.co/yefJ4zYiB4
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co…
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co…
Great Paper @felixfengmd Big change in how we subtype the disease: Luminal and Basal Subtyping of #ProstateCancer https://t.co/RZZIdedIia
"Luminal and Basal Subtyping of Prostate Cancer" https://t.co/Ojqef1SixZ
RT @JAMAOnc: Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co…
Luminal/basal subtyping of #ProstateCancer is prognostic for clin outcomes & predictive of post-op benefit of ADT https://t.co/npJnI1oQSt